Search research articles
Contact Us
Filters
Showing results (1-10 of 48) with videos related to
Page
of 5
Sort By:
Science (New York, N.Y.)
|
June 4, 2021
Antibody sugars are bittersweet
Ruklanthi de Alwis, Eng Eong Ooi
Methods in Molecular Biology (Clifton, N.J.)
|
April 4, 2014
Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique
Ruklanthi de Alwis, Aravinda M de Silva
Current Treatment Options in Infectious Diseases
|
August 25, 2020
Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever
Amanda Makha Bifani, Eugenia Z Ong, Ruklanthi de Alwis
Current Treatment Options in Infectious Diseases
|
November 11, 2020
Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever
Amanda Makha Bifani, Eugenia Z Ong, Ruklanthi de Alwis
Pathogens (Basel, Switzerland)
|
May 28, 2022
Phage ImmunoPrecipitation Sequencing (PhIP-Seq): The Promise of High Throughput Serology
Charles Kevin Tiu, Feng Zhu, Lin-Fa Wang, et al.
Ebiomedicine
|
April 29, 2020
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
Ruklanthi de Alwis, Shiwei Chen, Esther S Gan, et al.
Journal of Virology
|
August 8, 2014
Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones
Scott A Smith, A Ruklanthi de Alwis, Nurgun Kose, et al.
The Journal of Infectious Diseases
|
March 26, 2013
Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics
Scott A Smith, Ruklanthi de Alwis, Nurgun Kose, et al.
Plos Pathogens
|
March 25, 2010
Natural strain variation and antibody neutralization of dengue serotype 3 viruses
Wahala M P B Wahala, Eric F Donaldson, Ruklanthi de Alwis, et al.
JCI Insight
|
September 28, 2021
Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine
Roland Tschismarov, Raphaël M Zellweger, Min Jie Koh, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 48) with videos related to
Sort By:
Page
of 5
Science (New York, N.Y.)
|
June 4, 2021
Antibody sugars are bittersweet
Ruklanthi de Alwis, Eng Eong Ooi
Methods in Molecular Biology (Clifton, N.J.)
|
April 4, 2014
Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique
Ruklanthi de Alwis, Aravinda M de Silva
Current Treatment Options in Infectious Diseases
|
August 25, 2020
Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever
Amanda Makha Bifani, Eugenia Z Ong, Ruklanthi de Alwis
Current Treatment Options in Infectious Diseases
|
November 11, 2020
Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever
Amanda Makha Bifani, Eugenia Z Ong, Ruklanthi de Alwis
Pathogens (Basel, Switzerland)
|
May 28, 2022
Phage ImmunoPrecipitation Sequencing (PhIP-Seq): The Promise of High Throughput Serology
Charles Kevin Tiu, Feng Zhu, Lin-Fa Wang, et al.
Ebiomedicine
|
April 29, 2020
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
Ruklanthi de Alwis, Shiwei Chen, Esther S Gan, et al.
Journal of Virology
|
August 8, 2014
Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones
Scott A Smith, A Ruklanthi de Alwis, Nurgun Kose, et al.
The Journal of Infectious Diseases
|
March 26, 2013
Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics
Scott A Smith, Ruklanthi de Alwis, Nurgun Kose, et al.
Plos Pathogens
|
March 25, 2010
Natural strain variation and antibody neutralization of dengue serotype 3 viruses
Wahala M P B Wahala, Eric F Donaldson, Ruklanthi de Alwis, et al.
JCI Insight
|
September 28, 2021
Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine
Roland Tschismarov, Raphaël M Zellweger, Min Jie Koh, et al.
Page
of 5